Status:
COMPLETED
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Pharmacyclics LLC.
Conditions:
Non-Small-Cell Lung Carcinoma
Carcinoma, Bronchogenic
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to determine the dose limiting toxicities and maximum tolerated dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with Non-small Cell ...
Eligibility Criteria
Inclusion
- ≥ 18 years old
- ECOG score of 0, 1, or 2
- Histologically confirmed diagnosis of non-small cell lung cancer
Exclusion
- Laboratory values demonstrating inadequate function of the following:
- Bone marrow
- Kidneys
- Liver
- and
- Peripheral neuropathy Grade 2 or higher
- Greater than 2 prior chemotherapy regimens
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00102505
Start Date
November 1 2004
Last Update
April 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030